Study aim. The therapeutic efficacy and tolerance of agomelatine (Valdoxan) in mild and moderate depressive states were studied in out-patient conditions in a contingent of elderly patients. Materials and methods. Patients aged 60–75 years with mild and moderate depression (ICD-10) were treated with agomelatine. Agomelatine was given at doses of 25–50 mg/day as a single evening dose for six weeks. Results. The therapeutic effect of agomelatine was clearly apparent within two weeks of starting treatment. Agomelatine had a balanced spectrum of action in relation to symptoms of anxiety and depression, significantly improving patients’ quality of life measures. It had no negative influences on cognitive functions and there were no serious adverse events. Conclusions. The results obtained here allow agomelatine to be recommended for use in out-patient practice for the treatment of elderly patients with mild and moderate depressive disorders.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
S. I. Gavrilova and Ya. B. Kalyn, “Social-environmental factors and mental health status in the elderly population (a clinical-epidemiological study),” Vestn. Ros. Akad. Med. Nauk., No. 9, 15–20 (2002).
B. Sheehan, S. Karim, and A. Burns, “Mood disorders,” in: Old Age Psychiatry, Oxford Univ. Press (2009), pp. 95–124.
D. G. Blazer, “Depression in late life: review and commentary,” J. Gerontol. A. Biol. Med. Sci., 58, 249–265 (2003).
D. Eser, T. C. Baghai, and H. J. Möller, “Agomelatine: The evidence for its place in the treatment of depression,” Core Evid., 15, No. 4, 171–179 (2010).
J. E. Ware, M. Kosinski, and S. D. Keller, SF-36 Physical and Mental Health Summary Scales: A User’s Manual, The Health Institute, New England Medical Center, Boston, Mass (1994).
A. O. Nedoshivin, A. E. Kutuzova, N. N. Petrova, et al., “Studies of quality of life and psychological status in patients which chronic cardiac failure,” Serdech. Nedost., No. 4, 19–23 (2000).
N. M. Mikhailova, I. V. Kolykhalov, Ya. B. Kalyn, and G. A. Zharikov, “Studies of the use of Remeron in gerontological psychiatry,” Psikhiatr. Psikhofarmakoter., No. 2, 57–61 (2001).
N. D. Selezneva, S. I. Gavrilova, I. V. Kolykhalov, et al., “A trial of the clinical use of Cipralex neuron out-patient gerontopsychiatric practice,” Psikhiatr. Psikhofarmakoter., No. 6, 20–25 (2007).
S. Hale, R. M. Corral, C. Mencacci, et al., “Superior antidepressant effi cacy results of agomelatine versus fl uoxetine in severe MDD patients: a randomized, double-blind study,” Int. Clin. Psychophar macol., 25, 305–314 (2010).
S. Kasper, G. Hajak, K. Wulff, et al., “Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle, depressive and anxiety symptoms in patients with major depressive disorder. A randomized, double-blind comparison with sertraline,” J. Clin. Psychiatry, 71, 109–120 (2010).
M. A. Quera-Salva, G. Hajak, P. Philip, et al., “Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and effi cacy in major depressive disorder patients,” Int. Clin. Psychopharmacol., 26, No. 5, 252–262 (2011).
P. Lemoine, C. Guilleminault, and E. Alvarez, “Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine,” J. Clin. Psychiatry, 68, 1723–1732 (2007).
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 114, No. 9, Iss. I, pp. 43–48, September, 2014.
Rights and permissions
About this article
Cite this article
Gavrilova, S.I., Kolykhalov, I.V., Ponomareva, E.V. et al. A Clinical Trial of the Use of Agomelatine for the Treatment of Depression in Elderly Patients in Out-Patient Conditions. Neurosci Behav Physi 46, 365–370 (2016). https://doi.org/10.1007/s11055-016-0243-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11055-016-0243-8